贝达药业：帕妥珠单抗目前处于正常审评审批中

Group 1 - The core issue raised by investors is the pause in the progress of Pertuzumab after the company's involvement, which was previously going smoothly [2] - The company, Betta Pharmaceuticals (300558.SZ), responded that Pertuzumab is currently undergoing normal review and approval processes, and any significant developments will be disclosed in a timely manner [2]